Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137771 | 0.88 | EGFR (0.47) | EGFRERBB2HCAR2MAPTALDH1A1 | |
| SCHEMBL68412 | 0.88 | L3MBTL1 (0.50) | MAPTALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL18945510 | 0.84 | EPHX2 (0.46) | MAPTALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL20241752 | 0.84 | GLA (0.53) | EGFRERBB2MAPTALDH1A1KDM4E | |
| SCHEMBL7637921 | 0.84 | EGFR (0.49) | EGFRERBB2HCAR2MAPTALDH1A1 | |
| SCHEMBL1511063 | 0.84 | CYP4F2 (0.55) | EGFRL3MBTL1TDP1THRB | |
| SCHEMBL3835642 | 0.83 | KDM4E (0.39) | EGFRERBB2HCAR2MAPTALDH1A1 | |
| SCHEMBL31074140 | 0.83 | CYP4F2 (0.48) | ALDH1A1MAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1125421 | 0.83 | CYP4F2 (0.48) | ALDH1A1MAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8139240 | 0.83 | ALDH1A1 (0.53) | HCAR2MAPTALDH1A1KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102421742-B | Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof | PROMETIC BIOSCIENCES INC | 2014-08-06 | — | — | CN | claimed |
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12565511-B2 | SOS1 inhibitor containing phosphorus | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2026-03-03 | — | — | US | disclosed |
| US-12552770-B2 | Compounds for treating respiratory disease | TMEM16A LIMITED (GB) | 2026-02-17 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12419962-B2 | Quinazolines, pharmaceutical compositions, and therapeutic applications | BIOTHERYX, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4562015-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-5591858-A | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity | ALLERGAN | 1997-01-07 | — | — | US | disclosed |
| WO-1996033716-A1 | RARβ SELECTIVE RETINOID COMPOUNDS FOR INHIBITING GENE EXPRESSION PROMOTED BY AP1 PROTEIN AND THEIR USE IN THERAPY | ALLERGAN (US) | 1996-10-31 | — | — | WO | disclosed |
| US-5543534-A | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity | ALLERGAN | 1996-08-06 | — | — | US | disclosed |
| WO-1996020930-A1 | ACETYLENES DISUBSTITUTED WITH A 5 OR 8 SUBSTITUTED TETRAHYDRONAPHTHYL OR DIHYDRONAPHTHYL GROUP AND WITH AN ARYL OR HETEROARYL GROUPS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-07-11 | — | — | WO | disclosed |
| US-5514825-A | SYNTHETIC RETINOIDS | ALLERGAN, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| WO-1996011911-A1 | 5-LIPOXYGENASE INHIBITORS | PFIZER INC. (US) | 1996-04-25 | — | — | WO | disclosed |
| US-5489584-A | ANTIINFLAMMATORY AGENTS, ANTICARCINOGENIC AGENTS; TREATING SKIN DISORDER, CARDIOVASCULAR DISORDER | ALLERGAN, INC. (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0683781-A1 | NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE | GENSIA PHARMACEUTICALS, INC. (US) | 1995-11-29 | — | — | EP | disclosed |
| WO-1994018200-A1 | NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE | GENSIA, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| US-5087631-A | Vasodilators for treating cardiovascular disorders | GLAXO INC. (US) | 1992-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419962-B2 | Quinazolines, pharmaceutical compositions, and therapeutic applications | RAB1A, SOS1, IQGAP1 | EGFR 4404/4885ERBB2 3542/4885HCAR2 3470/4885 |
| US-12552770-B2 | Compounds for treating respiratory disease | TMEM109, SCN1A, SLC16A1 | EGFR 2101/4885ERBB2 2291/4885HCAR2 396/4885 |
| US-12565511-B2 | SOS1 inhibitor containing phosphorus | SOST, SOS1, SOS2 | EGFR 1304/4885ERBB2 1707/4885HCAR2 3458/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | EGFR 3358/4885ERBB2 2407/4885HCAR2 1377/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | EGFR 2608/4885ERBB2 2397/4885HCAR2 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.